Latest News
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering use of its lead clinical candidate, GLIX1, in cance...
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
19 November 2025 - Biopharmaceutical company Mycovia Pharmaceuticals Inc announced on Tuesday that long-term efficacy results from an extension study of the VIOLET Phase 3 clinical programme, which evaluated VIVJOA (oteseconazole) capsules in women w...
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
19 November 2025 - BioNet, a biotechnology company developing and manufacturing next generation vaccines including recombinant and mRNA vaccines, announced on Tuesday that it has received positive opinion from the Committee for Medicinal Products for...
Aetna to launch generative AI-powered conversational experience
19 November 2025 - Aetna, a CVS Health company (NYSE:CVS), announced on Tuesday that it is introducing a generative AI-powered conversational experience in its digital channels designed to simplify healthcare.This offering will allow members to quick...
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination
19 November 2025 - US-based pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has received approval from the US Food and Drug Administration for EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcu...